Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXVIII/228: 354-359 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2015, XXXVIII/228: 354-359

Title: Gout – from pathogenesis to treatment – progress in the XXI century 

Authors: Cal-Kocikowska J, Nawrocka M, Bogdański P.

More details

11/228

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Gout – from pathogenesis to treatment – progress in the XXI century


Cal-Kocikowska J1, Nawrocka M1, Bogdański P2.

Medical University of Poznan, Poland: 1Department of Internal Medicine, Metabolic Disorders and Hypertension; 2Department of Education and Treatment of Obesity and Metabolic Disorders

Gout has recently become the most common arthritis in developed countries. However studies indicate that treatment of gout is still insufficient. New discoveries including the role of inflammasome, inflammatory cytokines ( Il1β, IL-8,TNF–α), but also identification of the URAT -1 transporter or genetic mutation of SLC2A9 has given better understanding of the pathophysiology of gout and enable to use new therapies. New options in treatment significantly reduced the number of patients resistant to existing procedures, and created opportunities for a better individualization of the treatment. In this authors article in a practical way try to summary knowledge about the pathogenesis of the disease and the current guidelines for the diagnosis, the treatment of non-pharmacological and pharmacological treatment.

Key words: gout, hyperuricemia, allopurinol, febuxostat

Pol Med J, 2015; XXXVIII (228); 354–359